Louis G. Lange - 01 Jun 2025 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Reporting relationship: Director
Issuer ticker: NAMS
Reported as of: 01 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jun 2025, 16:59:38 UTC
Prior SEC filing: 02 May 2025
Next SEC filing: 09 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Louise Kooij by Power of Attorney from Louis G. Lange

Key filing fact

Louis G. Lange filed Form 4 for NewAmsterdam Pharma Co N.V. (NAMS) on 03 Jun 2025.

Key facts

This page summarizes Louis G. Lange's Form 4 filing for NewAmsterdam Pharma Co N.V. (NAMS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Jun 2025, 16:59.

Change

Previous filing in this sequence was filed on 02 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001238401 Primary reporting owner

LANGE LOUIS G

Relationship: Director
Address: C/O NEWAMSTERDAM PHARMA COMPANY N.V., GOOIMEER 2-35, NAARDEN, NETHERLANDS
Signature: /s/ Louise Kooij by Power of Attorney from Louis G. Lange
Signature date: 03 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NAMS transaction

Ordinary Shares

Options Exercise

Transaction value: $0
Shares: +68
Change %: +0.24%
Price: $0.000000
Shares after: 28,186
Date: 01 Jun 2025
Ownership: See Footnote
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NAMS transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value
Shares: -68
Change %: -100%
Price
Shares after: 0
Date: 01 Jun 2025
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 68
Exercise price
Footnotes: F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The shares are held directly by LGLange III Trust DTD10 (the "Trust") for the benefit of the Reporting Person.

Footnote F2

Each RSU represents a contingent right to receive one ordinary share.

Footnote F3

3,102 RSUs vested upon grant, 69 RSUs vested on April 1, 2025,69 RSUs vested on May 1, 2025 and 68 RSUs vested on June 1, 2025.

Footnote F4

The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date under the BCA (the "Closing Date"). The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date.